Search
rucaparib (Rubraca)
Indications:
- deleterious BRCA mutation associated advanced ovarian cancer in patients treated with >= 2 chemotherapies [1]
- androgen-independent metastatic prostate cancer
Dosage:
- 600 mg PO BID
Tablets: 300 mg
Laboratory:
- companion diagnostic test identifies alterations in BRCA1 & BRCA2 genes in ovarian tumor tissue
Adverse effects:
- fatigue (including asthenia),
- nausea, vomiting, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea
- dyspnea
- anemia, thrombocytopenia
- myelodysplastic syndrome/acute myeloid leukemia (0.5%) [1]
- hepatotoxicity [2]
Mechanism of action:
- inhibits poly ADP ribose polymerase (PARP inhibitor)
General
small inhibitory antineoplastic agent (ib drug)
PARP inhibitor
Database Correlations
PUBCHEM correlations
References
- FDA: Drugs: Rucaparib. December 19, 2016
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
- Bankhead C
Another Win for PARP Inhibition in Ovarian Cancer
Rucaparib maintenance extends PFS in all subgroups.
MedPage Today. September 11, 2017
https://www.medpagetoday.com/MeetingCoverage/ESMO/67807